Shotaro Komamura
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Research Interests
Shotaro Komamura has a total of 12 co-authors. Here are the top co-authors by number of shared publications:
- Hiroshi Sawaguchi
Department of Medicine, Division of Gastroenterology and Hepatology, Shinshu University School of Medicine, Matsumoto 390-8621, Japan
1 shared publication - Hiroyoshi Ota
Department of Clinical Laboratory Sciences, Shinshu University School of Medicine, Matsumoto, Japan
1 shared publication - Mai Iwaya
Department of Laboratory Medicine, Shinshu University Hospital, Matsumoto, Japan
1 shared publication - Masato Kitazawa
Division of Gastroenterological, Hepato-Biliary-Pancreatic, Transplantation and Pediatric Surgery, Department of Surgery, Shinshu University School of Medicine, Matsumoto, Japan
1 shared publication - Shiho Asaka
Department of Laboratory Medicine Shinshu University Hospital Matsumoto Japan
1 shared publication - Shinsuke Sugenoya
Department of Surgery, Division of Gastroenterological, Hepato-Biliary-Pancreatic, Transplantation and Pediatric Surgery, Shinshu University School of Medicine, Matsumoto 390-8621, Japan
1 shared publication
Latest Publications
- Open Access
The Correlation of PBK Expression with an Immune-Activated Tumor Microenvironment and Outcome in Colorectal Cancer
Background/Objectives: PDZ-binding kinase (PBK) regulates mitosis, but its clinical significance and cellular localization in colorectal cancer (CRC) remain unclear. We evaluated PBK expression in CRC tissues and examined its association with clinicopathological features, immune contexture, and outcomes. Methods: PBK expression was assessed by RNA in situ hybridization in tumors from 246 CRC patients. Associations with TNM stage, vascular invasion, MMR status (dMMR/pMMR), immune cell infiltration, and stromal programmed death-ligand 1 (PD-L1) were analyzed. Overall survival (OS) and recurrence-free survival (RFS) were evaluated using Kaplan–Meier and Cox models. Public single-cell RNA sequencing datasets were analyzed to identify PBK-expressing cell populations. Results: Among 246 cases, 75 (30.5%) showed high PBK expression. High PBK expression was associated with lower TNM stage, absence of vascular invasion, and dMMR status. High-PBK tumors showed an immune-activated microenvironment, including increased CD4+, CD8+, and FOXP3+ T-cell infiltration, higher stromal PD-L1 expression, and higher tumor-infiltrating lymphocyte scores. Single-cell analysis indicated that PBK expression was enriched mainly in proliferative tumor epithelial cell populations. High PBK expression was associated with longer OS and RFS and remained an independent favorable prognostic factor in multivariate analysis. Conclusions: PBK expression in CRC is linked to proliferative tumor epithelial states, an immune-activated microenvironment, and favorable outcomes, supporting its utility as a prognostic biomarker.
Open AccessThe Correlation of PBK Expression with an Immune-Activated Tumor Microenvironment and Outcome in Colorectal Cancer
Background/Objectives: PDZ-binding kinase (PBK) regulates mitosis, but its clinical significance and cellular localization in colorectal cancer (CRC) remain unclear. We evaluated PBK expression in CRC tissues and examined its association with clinicopathological features, immune contexture, and outcomes. Methods: PBK expression was assessed by RNA in situ hybridization in tumors from 246 CRC patients. Associations with TNM stage, vascular invasion, MMR status (dMMR/pMMR), immune cell infiltration, and stromal programmed death-ligand 1 (PD-L1) were analyzed. Overall survival (OS) and recurrence-free survival (RFS) were evaluated using Kaplan–Meier and Cox models. Public single-cell RNA sequencing datasets were analyzed to identify PBK-expressing cell populations. Results: Among 246 cases, 75 (30.5%) showed high PBK expression. High PBK expression was associated with lower TNM stage, absence of vascular invasion, and dMMR status. High-PBK tumors showed an immune-activated microenvironment, including increased CD4+, CD8+, and FOXP3+ T-cell infiltration, higher stromal PD-L1 expression, and higher tumor-infiltrating lymphocyte scores. Single-cell analysis indicated that PBK expression was enriched mainly in proliferative tumor epithelial cell populations. High PBK expression was associated with longer OS and RFS and remained an independent favorable prognostic factor in multivariate analysis. Conclusions: PBK expression in CRC is linked to proliferative tumor epithelial states, an immune-activated microenvironment, and favorable outcomes, supporting its utility as a prognostic biomarker.